Molecular mechanism for Alzheimer’s disease : searching for the possible therapeutic targets Sungkwon Chung Dept. of Physiology Sungkyunkwan Univ. School.

Slides:



Advertisements
Similar presentations
APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.
Advertisements

Alzheimer’s Disease Edwin Onattu P. 3.
Etiopathogenesis of Alzheimer's disease
ALZHEIMER’S DISEASE Erin Dancey. Overview Alzheimer’s is the most common cause of dementia in adult life and is associated with the selective damage of.
Genetic Screening for Alzheimer’s Disease Thorstensen: Genetic Screening for Alzheimer's Disease 1.
ALZHEIMER'S DISEASE (AD)
Neurobiology of Learning and Memory Prof. Anagnostaras Lecture 10: Alzheimer’s Disease and Cognitive Decline in Aging.
CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.
The Role of Beta Amyloid proteins in Alzheimer’s Disease What is A.D.?
Amyloid beta protein may initiate a cascade leading to AD pathology.
Alzheimer's Disease Your Name. Understanding Alzheimer's In 1906 Dr. Alois Alzheimer was first to describe Alzheimer's illness. Since then millions of.
Alzheimer’s Disease Nicotine’s relationship and contribution to dementia.
Alzheimer’s Disease Find group of ~4 students ~ 10 minutes Discuss the following personal family connection to AD (if willing only) observations/experiences.
ALZHEIMER’S AND DOWN’S SYNDROME
Alzheimer’s Disease: Genetics, Pathogenesis, Models, and Experimental Therapeutics.
Alzheimer’s Disease By: Ryan Triplett. Alzheimer’s The deterioration of intellectual capabilities, memory, judgment, and personality to the extent that.
Dr. Amr Moustafa Biochemistry Unit Department of Pathology.
Alzheimer's disease Beta amyloid protein and the potential for anti-oxidants drugs.
Genes, Environment- Lifestyle, and Common Diseases Chapter 5.
Decision presented by the committee board members: Nicholas Mann & Katelyn Strasser FUTURE FUNDING FOR ALZHEIMER’S DISEASE October 14, 2014 MPH 543 Leadership.
ALZHEIMER’S DISEASE BY OLUFOLAKUNMI KEHINDE PRE-MD 1.
Nature may have the answers for Alzheimer’s disease Sungkwon Chung Dept. of Physiology Sungkyunkwan University School of Medicine.
ALZHEIMER’S DISEASE BY JOSEPH MOLLUSO.
Alzheimer’s Disease Landscape
Progress Report on Alzheimer’s Disease Taking the Next Steps NIA NIH.
By: Tasso Skountzouris David Schiano. General Description  Alzheimer’s is one the most common form of Dementia  Dementia causes a loss of brain function.
COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.
Introduction Alzheimer’s is a disease that affects the brain. About 4 million people in the United States have it. It is predicted that 1 in 85 people.
WHAT DO YOU REMEMBER ABOUT ALZHEIMER’S DEMENTIA?.
Introduction Alzheimer’s disease (AD) is a neurodegenerative disease associated with brain shrinkage and the loss of neurons, particularly cholinergic.
Alzheimer’s Disease -> The Disease of Darkness Varun Doshi.
Alzheimer’s Disease By: Chelcy Branon. Facts  In 2006, there were 26.6 million sufferers worldwide  Costs 100 billion dollars per year.
Dr. Usman Ghani CNS Block.  Pathophysiology of alzheimer’s disease: 5I.
10 signs to early detection 1. Memory loss that affects daily life 2. Challenges in planning or solving problems 3. Difficulty completing projects at.
Trafficking and processing of APP  -secretase. Intracellular trafficking of APP: relation to its physiological function?
ALZHIEMERS DISEASE IN UK ‘’The Dementia Time bomb’’ By VISHAL ZAVERI AND ORE AJAI.
1 Genes, Environment- Lifestyle, and Common Diseases Chapter 5.
Dementia 痴呆 Jie Ming Shen, M.D., Ph.D. Department of Neurology Ruijin Hospital, SSMU.
11-3 Part Two: Health, Dementia, and Alzheimer’s Disease.
NEUROLOGICAL DISORDERS. Dementia  A degenerative syndrome characterized by deficits in memory, language, and mood.  The most common form: Alzheimer’s.
?v=pQO3Tq3KQL4 ohlTE.
Alzheimer’s Disease By: Nora Teen Health 8 Period 1.
National Institute on Aging
Dr. Sigal fleisher-Berkovich Neuroinflammation is regulated by angiotensin related drugs: possible implications for neurodegenerative diseases.
CLINICAL AND RESEARCH MEMORY CENTER LARIBOISIERE HOSPITAL PARIS FRANCE UNIVERSITY OF PARIS DIDEROT INSERM UNIT 942 INVOLVEMENT OF PKR IN ALZHEIMER’S DISEASE.
Alzheimer’s Disease Gavin Mast, Musa Abdus-Samad, Arash Rezaeian, Sarah Rocha PHM142 Fall 2015 Instructor: Dr. Jeffrey Henderson.
Neurological Disorders
Epidemiology of Alzheimer’s Disease
PD – Circuitry changes PD HD Normal. Causes of PD  Genetics  Several identified mutations associated with PD  LRRK2 mutations – some are autosomal.
Under the supervision of miklós jászberényi
Alzheimer's disease M O Jamali, H Saeed & T Mathew.
Cognitive Disorders Chapter 13 Nature of Cognitive Disorders: An Overview Perspectives on Cognitive Disorders Cognitive processes such as learning, memory,
Alzheimer’s Disease and the influence of Presenilin 1 By Tony Cortez.
Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.
Alzheimer’s Disease By Evelyn B. Kelly 2-7 Healthy Brain Advanced Alzheimer ’ s.
Alzheimer's disease 蕭尚益 丁唯洋 蔡欣容. Outline introductionDisease mechanismPreventConclusion.
Sortilin-related receptor and Alzheimer’s disease
Genetic aspects of Alzheimer disease Karolina Pesz, Błażej Misiak, Maria M. Sasiadek Department of Genetics Wroclaw Medical University, Poland.
Alzheimer’s Disease (AD)
Measuring the Effect of Silencing the APP gene and Stimulating the CaMKII Pathway on Synaptic Plasticity in Alzheimer’s Disease Harshita Nangunuri.
Alzheimer’s Disease and the influence of Presenilin 1
Alzheimer’s Disease and Cholesterol
Alzheimer’s Disease Dr. Usman Ghani CNS Block.
Alzheimer’s Disease CNS Block.
Neurodegeneration caused by prions. A
Alzheimer’s Disease 1 in 9 people in the US aged 65 and older
Progress Report on Alzheimer’s Disease
Alzheimer’s Disease and the influence of Presenilin 1
Neuroplasticity Failure in Alzheimer's Disease
Alzheimer’s Disease Dr. Usman Ghani Neuropsychiatry Block.
Presentation transcript:

Molecular mechanism for Alzheimer’s disease : searching for the possible therapeutic targets Sungkwon Chung Dept. of Physiology Sungkyunkwan Univ. School of Medicine

Facts on Alzheimer’s disease (AD)  It attacks and slowly steals the minds of its victims.  Symptoms of the disease include: memory lossconfusion impaired judgment personality changes disorientationloss of language skills.  Always fatal, Alzheimer's disease is the most common form of irreversible dementia.  years : 10%, 75-84: 20%, 85 and older: 50% It is estimated that by 2020, 30 million people will be affected by this devastating disorder worldwide and by 2050, the number could increase to 45 million.

Facts on Alzheimer’s disease (AD)  The average cost for nursing home care is $42,000 per year, and the average lifetime cost of care for an individual with Alzheimer’s is $174,000. Medicare costs for beneficiaries with Alzheimer’s are over $100 billion.  Alzheimer's disease is a progressive, irreversible brain disorder with no known cause or cure. National Institute on Aging Alzheimer's Disease, Causes and Risk Factors “Scientists do not yet fully understand what causes Alzheimer's disease. There probably is not one single cause, but several factors that affect each person differently.”

Alzheimer’s disease  sporadic (late on-set): > 95% of patients - Epidemiological Factors Hypercholesterolaemia Hypertension Hyperrhomocysteinaemia Diabete mellitus Metabolic syndrome Smoking Systemic inflammation Increased fat intake and obesity  genetic (early on-set): < 5% of patients (FAD) - ApoE ε4 polymorphism - mutations in APP - mutations in presenilin 1, 2 (PS1, PS2)

Amyloid plaques and Neurofibrillary tangles

Amyloid cascade hypothesis

Amyloid Precursor Protein (APP) and its metabolites Citron, Nature Rev. Neurosci., 2004 APP → Aβ Notch1 → NICD p75 NTR → p75-ICD

Roberson & Nucke, Science, 2006

Q1: Even though potent inhibitors for γ-secretase had been developed, it could not be used for the patients. Why?

I.Functional role of presenilin in Ca 2+ regulation

The core of the  -secretase complex

Yoo et al., 2000 Presenilin as negative regulator of capacitative Ca 2+ entry (CCE)

Effect of a CCE inhibitor, SKF, on A  42 generation

Presenilin as part of  -secretase Presenilin as negative regulator of CCE Leissring et al., J.C.B., 2000 Yoo et al., Neuron, 2000  CCE pathway may serve as a putative therapeutic target for Alzheimer’s disease.

II. Finding molecular identity of CCE

Down-regulation of I MIC in FAD PS mutants AB CD wt PS M146L L286V ∆E9 I MIC (pA/pF) Time (s) * ∆E9 * L286V wt PS I MIC (pA/pF) I CRAC (pA/pF) ∆ E9 wt PS L286V wt PS M146L L286V ∆E9 Time (s) I /I of I MAX MIC

Recovery of I MIC from PS mutant cells by PIP 2

P P P PI(4,5)P2PI(4)PPI(3,4,5)P3 P P P IP 3 + DAG PI(4,5)P2 PLC

Down-regulation of PIP 2 in PS mutant cells

Correlation of the level of PIP 2 and Aβ42 generation

 TRPM7-like MIC currents underlie the mechanism for PS-mediated modulation of Ca 2+ influx.  The down-regulation of PIP 2 levels and the generation of Aβ42 were correlated.  Up-regulation of PIP 2 levels will be a possible therapeutic target Alzheimer’s disease.

III. Ginsenoside: Modulator for  -secretase via PIP 2

Structure & function of gisenosides

A  42-lowering effect of Rg3

A  42-lowering effect of ginsenosides

A  42-lowering effect of Rg3, Rk1

A  42-lowering effect of Rg3 is specific for APP

Increase of PI(4)P by Rg3

Increase of PI(4)P by Rg3 via activation of PI4KII 

PI4KII  decreases production of A  42

A  42-lowering effect of Rg3 in vivo

← PI4KII  ↑← Rg3

IV. Activator for  -secretase?  42, sAPP  ELISA assay

MeOH extract (CN1-M) BuOH (B) EtOAc (E) Hexane (H) Dichloromethane (M) HPCL Fractions (E1, E2, E3, E4) E1 HPCL Fractions (1,2,3,4,5,6)

Dose dependent effect of E1-4-4 on A  42 and A  40 secretion

CN1-M-E1-4-4 increases sAPP , and decreases sAPP 

 -secretase or  -secretase monoclonal antibody Cell-free

CN1-M-E1-4-4 may directly activates  -secretase

Q2: Amyloidogenic Aβ42 is produced by the activity of γ- secretase. However, activators for  -secretase is considered as good therapeutic drug. Why?